Related Experiment Video
Updated: Jun 3, 2026
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Increased prefrontal volume in PD with levodopa-induced dyskinesias: a voxel-based morphometry study
Antonio Cerasa1, Demetrio Messina, Pierfrancesco Pugliese
1Neuroimaging Research Unit, Institute of Neurological Sciences, National Research Council, Germaneto (CZ), Italy.
Summary
Levodopa-induced dyskinesias in Parkinson's disease patients show increased gray matter in the inferior frontal gyrus. This suggests aberrant neural plasticity may contribute to these motor complications.
Area of Science:
- Neuroscience
- Neurology
- Radiology
Background:
- Levodopa-induced dyskinesias are disabling complications of Parkinson's disease (PD) treatment.
- The neuroanatomical basis of these motor complications remains unclear despite known striatofrontal function alterations.
Purpose of the Study:
- To investigate the neuroanatomical correlates of levodopa-induced dyskinesias in Parkinson's disease patients.
- To identify structural brain differences associated with dyskinesia development.
Main Methods:
- Optimized voxel-based morphometry (VBM) applied to MRI scans.
- Comparison of 36 PD patients with dyskinesias, 36 PD patients without dyskinesias, and 32 healthy controls.
Main Results:
- Increased gray matter volume in the bilateral inferior frontal gyrus was observed in PD patients with dyskinesias compared to those without.
- This finding was more pronounced in early-onset Parkinson's disease patients.
- No significant differences were found between dyskinetic/nondyskinetic PD groups and controls.
Conclusions:
- Aberrant neural plasticity, indicated by inferior frontal gyrus gray matter changes, may play a role in the pathophysiology of levodopa-induced dyskinesias.
- These structural alterations could be a biomarker for dyskinesia development in Parkinson's disease.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...